The Lancet NOVEMBER 16, 2005

Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study

Haruo Nakamura et al.

Bottom Line

The MEGA study demonstrated that low-dose pravastatin, in addition to diet, significantly reduced the incidence of coronary heart disease events in Japanese patients with mildly elevated cholesterol compared to diet alone.

Key Findings

1. Pravastatin treatment resulted in a 33% relative reduction in the primary composite endpoint of coronary heart disease events compared to diet alone (hazard ratio 0.67; 95% CI 0.49–0.91; P=0.01).

2. The primary endpoint occurred at a rate of 3.3 per 1,000 patient-years in the pravastatin group versus 5.0 per 1,000 patient-years in the diet-only group.

3. Myocardial infarction was significantly less frequent in the pravastatin group (0.9 vs. 1.6 per 1,000 patient-years, P=0.03).

4. Total mortality was numerically lower in the pravastatin group (2.7 vs. 3.8 per 1,000 patient-years, HR 0.72), although this did not reach statistical significance (P=0.055).

5. Pravastatin demonstrated efficacy despite a relatively modest reduction in LDL cholesterol (approximately 18% greater reduction than diet alone).

Study Design

Design

RCT

Open-Label, Blinded Endpoint

Sample

7,832

Patients

Duration

5.3 yr

Median

Setting

Multicenter, Japan

Population Japanese men and postmenopausal women (ages 40–70) with hypercholesterolemia (total cholesterol 220–270 mg/dL) and no history of coronary heart disease.

Intervention Pravastatin (10–20 mg/day) plus diet modification

Comparator Diet modification alone

Outcome Composite of coronary heart disease events, including cardiac and sudden death, fatal and nonfatal myocardial infarction, angina pectoris, and cardiac or vascular intervention.

Study Limitations

• The study utilized an open-label design with blinded endpoints, which may introduce potential biases compared to a double-blind, placebo-controlled trial.

• The population consisted of Japanese patients, which may limit the direct generalizability of findings to other ethnic groups with different baseline cardiovascular risk profiles.

• The relatively low event rate in this low-risk population required a large sample size and long follow-up to achieve sufficient power.

• The dose of pravastatin used was low (10–20 mg/day), reflecting regional clinical practice at the time rather than the more aggressive lipid-lowering regimens common in Western trials.

Clinical Significance

The MEGA study provided critical evidence that primary prevention with low-dose statin therapy is effective in Asian populations with mildly elevated cholesterol, suggesting that even patients at lower absolute cardiovascular risk can derive significant clinical benefit from lipid-lowering therapy.

Historical Context

Prior to the MEGA study, large-scale statin trials were conducted predominantly in Western populations with higher baseline cardiovascular risk. The MEGA study was the first major randomized controlled trial of statin therapy in Japan, addressing uncertainty regarding whether findings from Western trials were applicable to Japanese patients, who typically exhibit lower cardiovascular morbidity and mortality and potentially higher sensitivity to statin medication.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the biochemical mechanism of action for pravastatin, and how does its pharmacological profile differ from lipophilic statins like simvastatin in terms of cellular uptake?

Key Response

Pravastatin is an HMG-CoA reductase inhibitor that prevents the conversion of HMG-CoA to mevalonate. Unlike simvastatin, pravastatin is hydrophilic and enters hepatocytes primarily through active transport via OATP1B1 transporters rather than passive diffusion, which contributes to its lower risk of systemic myotoxicity and fewer drug-drug interactions involving the CYP450 system.

Resident

In the context of the MEGA study findings, how should a clinician approach the decision to initiate statin therapy in an East Asian patient with an LDL of 155 mg/dL compared to a Caucasian patient with the same level?

Key Response

The MEGA study demonstrated that Japanese patients derive significant cardiovascular benefit from much lower doses of statins (10-20mg pravastatin) than typically used in Western cohorts. Residents must recognize that 'low-intensity' therapy may be 'optimal-intensity' in certain ethnic populations due to higher drug sensitivity and lower baseline cardiovascular risk, necessitating a more nuanced application of ACC/AHA guidelines which are largely based on Western data.

Fellow

The MEGA study reported a 33% relative risk reduction in CHD events. How does the low absolute event rate in this population (approx. 0.5% per year) impact the Number Needed to Treat (NNT), and what does this imply for cost-effectiveness in primary prevention?

Key Response

While the relative risk reduction (RRR) was high, the low absolute risk in the Japanese population leads to a higher NNT (approximately 119 over 5 years for CHD events). Fellows must be able to distinguish between RRR and Absolute Risk Reduction (ARR) to integrate evidence into value-based care, recognizing that the threshold for 'cost-effective' intervention is much higher in low-incidence populations.

Attending

Considering the 'legacy effect' seen in long-term follow-ups of primary prevention trials, how does the MEGA study's use of low-intensity pravastatin challenge the current 'lower is better' dogma for LDL reduction in low-risk individuals?

Key Response

MEGA suggests that achieving a specific LDL target may be less important than the early initiation of any statin-mediated pleiotropic effects and modest LDL lowering in low-risk patients. For attendings, this serves as a teaching point on 'risk-based' versus 'target-based' treatment: in low-risk primary prevention, even minimal intervention can significantly shift the lifetime risk curve.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The MEGA study utilized a Prospective, Randomized, Open-label, Blinded Endpoint (PROBE) design. What are the specific threats to internal validity inherent in this design, and how does the use of an independent endpoint committee mitigate these risks?

Key Response

Open-label designs risk performance bias, where patients in the treatment arm may adopt healthier lifestyles (diet/exercise) because they know they are being treated. While blinded adjudication of 'hard' endpoints like MI or death minimizes detection bias, 'soft' endpoints like physician-driven revascularization remain susceptible to bias, potentially overestimating the treatment effect.

Journal Editor

If the MEGA study results were submitted today, how would the inclusion of 'stroke' as a secondary endpoint and the lack of a placebo control influence your assessment of the paper's impact factor and editorial priority?

Key Response

An editor would flag the lack of placebo control (diet-only arm) as a weakness in the 'double-blind' gold standard. However, the study's significance lies in its large-scale evaluation of an underrepresented population. The lack of significant reduction in stroke in MEGA—contrasting with Western trials—would be a key point for editorial discussion regarding population-specific disease manifestations (hemorrhagic vs. ischemic).

Guideline Committee

How do the results of the MEGA study support the divergence of Japanese Circulation Society (JCS) guidelines from the ACC/AHA guidelines regarding statin dosing and LDL targets for primary prevention?

Key Response

The MEGA study provides the evidence base for JCS guidelines to recommend lower starting doses of statins (e.g., 5-10mg pravastatin). Current ACC/AHA guidelines emphasize high-intensity statins for high-risk groups, but MEGA confirms that for East Asian primary prevention, the risk-benefit ratio favors lower doses due to equivalent RRR but lower thresholds for side effects compared to Western populations.

Clinical Landscape

Noteworthy Related Trials

1994

4S Trial

n = 4,444 · Lancet

Tested

Simvastatin

Population

Patients with coronary heart disease and hypercholesterolemia

Comparator

Placebo

Endpoint

All-cause mortality

Key result: Simvastatin treatment resulted in a 30% reduction in all-cause mortality and a 42% reduction in coronary deaths.

1995

WOSCOPS Trial

n = 6,595 · NEJM

Tested

Pravastatin 40mg daily

Population

Middle-aged men with hypercholesterolemia but no history of myocardial infarction

Comparator

Placebo

Endpoint

Nonfatal myocardial infarction or death from coronary heart disease

Key result: Pravastatin treatment significantly reduced the primary endpoint by 31% over five years.

2003

ASCOT-LLA Trial

n = 10,305 · Lancet

Tested

Atorvastatin 10mg daily

Population

Hypertensive patients with at least three other cardiovascular risk factors

Comparator

Placebo

Endpoint

Nonfatal myocardial infarction and fatal coronary heart disease

Key result: Treatment with atorvastatin resulted in a 36% reduction in major cardiovascular events compared to placebo.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis